{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:52:54Z","timestamp":1789501974751,"version":"build-2803163510"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/ftd.0b013e3182a04fc7","type":"journal-article","created":{"date-parts":[[2013,9,21]],"date-time":"2013-09-21T13:52:35Z","timestamp":1379771555000},"page":"93-99","source":"Crossref","is-referenced-by-count":65,"title":["Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation"],"prefix":"10.1097","volume":"36","author":[{"given":"Marc","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Th\u00e9oret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Aziz","family":"Rezgui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Mezziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Desjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Champagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Krajinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":". Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","article-title":". Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.","volume":"30","author":"McCune","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00688324","article-title":". Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.","volume":"37","author":"Vassal","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"R4-14-20210129","first-page":"225","article-title":". Association of busulfan area under the curve with veno-occlusive disease following BMT.","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"R5-14-20210129","first-page":"31","article-title":". Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":". Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":". Busulfan bioavailability.","volume":"84","author":"Hassan","year":"1994","journal-title":"Blood"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00689702","article-title":". Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.","volume":"28","author":"Hassan","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 3","key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1399-3046.7.s3.2.x","article-title":". Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.","volume":"7","author":"Bostrom","year":"2003","journal-title":"Pediatr Transplant"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.bmt.1703207","article-title":". Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.","volume":"28","author":"Bleyzac","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","article-title":". Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.","volume":"26","author":"Tran","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bmt.1703264","article-title":". Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.","volume":"28","author":"Bolinger","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-005-0029-0","article-title":". Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.","volume":"57","author":"Nguyen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":". Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","article-title":". High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.","volume":"14","author":"Geddes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001813-200503000-00014","article-title":". Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.","volume":"16","author":"Oechtering","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03166.x","article-title":". Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.","volume":"66","author":"Nath","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2006.10.026","article-title":". Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.","volume":"13","author":"Schechter","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2004.07.010","article-title":". Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.","volume":"10","author":"Tran","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1704707","article-title":". Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.","volume":"35","author":"Zwaveling","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/01.cad.0000231482.15277.48","article-title":". Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.","volume":"17","author":"Zwaveling","year":"2006","journal-title":"Anticancer Drugs"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bmt.2009.143","article-title":". Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.","volume":"45","author":"Ansari","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"R24-14-20210129","first-page":"1729","article-title":"Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation Pharmacogenomics.","volume":"10","author":"Ansari","year":"2009","journal-title":""},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":". Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transpl"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bmt.1704209","article-title":". Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.","volume":"32","author":"Dalle","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":". Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":". Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401921","article-title":". A phase III study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.","volume":"14","author":"Olavarria","year":"2000","journal-title":"Leukemia"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2125.2002.01555.x","article-title":". Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.","volume":"53","author":"Cremers","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R31-14-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00007691-199704000-00009","article-title":". Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection.","volume":"19","author":"Rifai","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R32-14-20210129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":". Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"R33-14-20210129","first-page":"825","article-title":". 1994 Consensus Conference on acute GVHD grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R34-14-20210129","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":". Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"R35-14-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/088800102753356167","article-title":". Therapeutic monitoring of busulfan in pediatric bone marrow transplantation.","volume":"19","author":"Krivoy","year":"2002","journal-title":"Pediatr Hematol Oncol"},{"key":"R36-14-20210129","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","article-title":"Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.","volume":"20","author":"Slattery","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R37-14-20210129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","article-title":". An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.","volume":"25","author":"Bolinger","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R38-14-20210129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bmt.1702590","article-title":". Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.","volume":"26","author":"Baker","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R39-14-20210129","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":". Graft-versus-host disease.","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"R40-14-20210129","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.bbmt.2011.02.011","article-title":". Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.","volume":"17","author":"Santarone","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R41-14-20210129","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3109\/10428194.2010.520773","article-title":". Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndromeveno-occlusive disease.","volume":"51","author":"ODonnell","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R42-14-20210129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/pbc.22959","article-title":". Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.","volume":"58","author":"Michel","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R43-14-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2010.06.017","article-title":". Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.","volume":"17","author":"Almog","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R44-14-20210129","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","article-title":". The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.","volume":"25","author":"Hassan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R45-14-20210129","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":". Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"R46-14-20210129","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","article-title":". Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.","volume":"13","author":"McCune","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R47-14-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":". Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R48-14-20210129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bmt.2010.137","article-title":". Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.","volume":"46","author":"Cantoni","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R49-14-20210129","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bmt.2010.190","article-title":". Targeted i.v. BU and fludarabine (t-i.v. BUFlu) provides effective control of AML in adults with reduced toxicity.","volume":"46","author":"Pidala","year":"2011","journal-title":"Bone Marrow Transplant"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182a04fc7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:41:20Z","timestamp":1620952880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201402000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182a04fc7","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}